RecruitingPHASE1, PHASE2NCT05669950
A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Studying Congenital adrenal hyperplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lundbeck A/S
- Principal Investigator
- Email contact via H. Lundbeck A/SHQ_Medinfo@Lundbeck.com
- Intervention
- Lu AG13909(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2022 – 2027
Study locations (17)
- University Hospital-University of Michigan, Ann Arbor, Michigan, United States
- Rigshospitalet, Copenhagen, Denmark
- Chu Angers, Angers, France
- CHU de Lille, Lille, France
- GH Pitié-Salpêtrière, Paris, France
- CHRU Strasbourg, Strasbourg, France
- David Metreveli Medical Centre, Tbilisi, Tbilisi, Georgia
- Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin, Dublin, Ireland
- Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Roma, Italy
- Centrum Nowoczesnych Terapii, Dobry Lekarz, Dobry Lekarz, Poland
- Sahlgrenska University Hospital, Gothenburg, Sweden
- Karolinska University Hospital, Stockholm, Sweden
- NIHR/Wellcome Trust Clinical Research Facility, Birmingham, United Kingdom
- Cambridge Clinical Research Centre, Cambridge, United Kingdom
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05669950 on ClinicalTrials.govOther trials for Congenital adrenal hyperplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07159841A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)Crinetics Pharmaceuticals Inc.
- RECRUITINGPHASE3NCT07144163A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaCrinetics Pharmaceuticals Inc.
- RECRUITINGPHASE2NCT07187375Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldNeurocrine Biosciences
- RECRUITINGNANCT07473804Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)IRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06712823An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894Crinetics Pharmaceuticals Inc.
- RECRUITINGNANCT07099456Fertility And Sexual Function In CAH: CALLIOPEUniversity of Roma La Sapienza
- RECRUITINGNCT06754423Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase DeficiencyIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04783181A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)Adrenas Therapeutics Inc